Cargando…
The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status
An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068984/ https://www.ncbi.nlm.nih.gov/pubmed/32169119 http://dx.doi.org/10.1186/s40779-020-00240-0 |
_version_ | 1783505686291808256 |
---|---|
author | Guo, Yan-Rong Cao, Qing-Dong Hong, Zhong-Si Tan, Yuan-Yang Chen, Shou-Deng Jin, Hong-Jun Tan, Kai-Sen Wang, De-Yun Yan, Yan |
author_facet | Guo, Yan-Rong Cao, Qing-Dong Hong, Zhong-Si Tan, Yuan-Yang Chen, Shou-Deng Jin, Hong-Jun Tan, Kai-Sen Wang, De-Yun Yan, Yan |
author_sort | Guo, Yan-Rong |
collection | PubMed |
description | An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus. |
format | Online Article Text |
id | pubmed-7068984 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-70689842020-03-18 The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status Guo, Yan-Rong Cao, Qing-Dong Hong, Zhong-Si Tan, Yuan-Yang Chen, Shou-Deng Jin, Hong-Jun Tan, Kai-Sen Wang, De-Yun Yan, Yan Mil Med Res Review An acute respiratory disease, caused by a novel coronavirus (SARS-CoV-2, previously known as 2019-nCoV), the coronavirus disease 2019 (COVID-19) has spread throughout China and received worldwide attention. On 30 January 2020, World Health Organization (WHO) officially declared the COVID-19 epidemic as a public health emergency of international concern. The emergence of SARS-CoV-2, since the severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002 and Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, marked the third introduction of a highly pathogenic and large-scale epidemic coronavirus into the human population in the twenty-first century. As of 1 March 2020, a total of 87,137 confirmed cases globally, 79,968 confirmed in China and 7169 outside of China, with 2977 deaths (3.4%) had been reported by WHO. Meanwhile, several independent research groups have identified that SARS-CoV-2 belongs to β-coronavirus, with highly identical genome to bat coronavirus, pointing to bat as the natural host. The novel coronavirus uses the same receptor, angiotensin-converting enzyme 2 (ACE2) as that for SARS-CoV, and mainly spreads through the respiratory tract. Importantly, increasingly evidence showed sustained human-to-human transmission, along with many exported cases across the globe. The clinical symptoms of COVID-19 patients include fever, cough, fatigue and a small population of patients appeared gastrointestinal infection symptoms. The elderly and people with underlying diseases are susceptible to infection and prone to serious outcomes, which may be associated with acute respiratory distress syndrome (ARDS) and cytokine storm. Currently, there are few specific antiviral strategies, but several potent candidates of antivirals and repurposed drugs are under urgent investigation. In this review, we summarized the latest research progress of the epidemiology, pathogenesis, and clinical characteristics of COVID-19, and discussed the current treatment and scientific advancements to combat the epidemic novel coronavirus. BioMed Central 2020-03-13 /pmc/articles/PMC7068984/ /pubmed/32169119 http://dx.doi.org/10.1186/s40779-020-00240-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Guo, Yan-Rong Cao, Qing-Dong Hong, Zhong-Si Tan, Yuan-Yang Chen, Shou-Deng Jin, Hong-Jun Tan, Kai-Sen Wang, De-Yun Yan, Yan The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
title | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
title_full | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
title_fullStr | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
title_full_unstemmed | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
title_short | The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status |
title_sort | origin, transmission and clinical therapies on coronavirus disease 2019 (covid-19) outbreak – an update on the status |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068984/ https://www.ncbi.nlm.nih.gov/pubmed/32169119 http://dx.doi.org/10.1186/s40779-020-00240-0 |
work_keys_str_mv | AT guoyanrong theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT caoqingdong theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT hongzhongsi theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT tanyuanyang theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT chenshoudeng theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT jinhongjun theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT tankaisen theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT wangdeyun theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT yanyan theorigintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT guoyanrong origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT caoqingdong origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT hongzhongsi origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT tanyuanyang origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT chenshoudeng origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT jinhongjun origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT tankaisen origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT wangdeyun origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus AT yanyan origintransmissionandclinicaltherapiesoncoronavirusdisease2019covid19outbreakanupdateonthestatus |